Table 1.

Baseline characteristics of the analytic cohort.

	Non-Black N=561	Black N=160	P-Value
Age, years	70 ± 12	59 ± 13	<0.0001
Male	418 (75)	110 (69)	0.1
Study			0.4
• ROSE-AHF	273 (80)	69 (20)
• DOSE-AHF	220 (77)	67 (23)
• CARRESS-HF	68 (74)	24 (26)
Hypertension	452 (81)	142 (89)	0.017
Diabetes mellitus	319 (57)	83 (52)	0.2
Nonischemic HF etiology	269 (48)	123 (77)	<0.0001
Ejection Fraction, %	38 ± 17	31 ± 16	<0.0001
Heart Failure with Preserved Ejection Fraction	184 (33)	33 (21)	0.003
Years since HF diagnosis	6.5 ± 6.6	4.6 ± 4.1	<0.0001
NYHA Class			0.9
• 1–2	20 (4)	6 (4)
• 3	343 (65.0	95 (66)
• 4	165 (31)	43 (30)
Baseline medical therapy
• ACEi/ARB	293 (53)	104 (65)	0.009
• Beta-blocker	451 (82)	141 (88)	0.07
• Aldosterone receptor antagonist	148 (27)	54 (34)	0.09
• Hydralazine	66 (12)	61 (38)	<0.0001
• Nitrates	134 (24)	68 (43)	<0.0001
• Digoxin	136 (25)	47 (29)	0.2
• Loop diuretic dose (mg furosemide equivalents)	120 (80, 160)	80 (80, 160)	0.1
• Sequential nephron blockade	74 (13)	12 (8)	0.049
Body mass index, kg/m²	33 ± 9	35 ± 11	0.017
Systolic blood pressure, mm Hg	117 ± 18	122 ± 20	0.005
Diastolic blood pressure, mm Hg	65 ± 12	74 ± 14	<0.0001
# CV hospitalizations in prior 12 months	1.7 ± 1.6	2.2 ± 2.1	0.006
# HF hospitalizations in prior 12 months	1.3 ± 1.4	1.9 ± 1.8	<0.0001
Serum chemistries
• Sodium, mg/dL	138.2 ± 3.8	137.5 ± 4.1	0.035
• Total bilirubin, mg/dL	1.1 ± 0.7	1.2 ± 0.8	0.3
• Blood urea nitrogen, mg/dL	39 (27, 56)	29( 19, 44)	<0.0001
• Creatinine, mg/dL	1.7 ± 0.6	1.7 ± 0.6	0.7
• eGFR, mL/min/1.72m²	46 ± 19	58 ± 26	0.7
• NT-pro BNP (pg/mL)	4,627 (2,273 – 9,833)	4,349 (2,369 – 9,709)	0.9
Days from randomization to discharge	6 (4, 9)	6 (4, 8)	0.5

Values are mean ± standard deviation, median (interquartile range), or N(%).